PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26616666-8	2015	At clinically relevant concentrations, verapamil blocked hCav1.2 and hERG, as did vanoxerine and bepridil both of which also blocked hNav1.5.	Bepridil	97-105	sodium voltage-gated channel alpha subunit 5	Homo sapiens	133-140	
20625312-0	2010	Efficacy of low-dose bepridil for prevention of ventricular fibrillation in patients with Brugada syndrome with and without SCN5A mutation.	Bepridil	21-29	sodium voltage-gated channel alpha subunit 5	Homo sapiens	124-129	
20625312-3	2010	Among 130 patients with Brugada-type electrocardiogram (ECG), low-dose bepridil was administered to seven patients because of repetitive VF episodes, including three with and four without SCN5A mutation.	Bepridil	71-79	sodium voltage-gated channel alpha subunit 5	Homo sapiens	188-193	
20625312-5	2010	Frequencies of VF episodes were reduced after treatment with low-dose bepridil in all three patients with the SCN5A mutation (before: 0.33 versus after: 0.02 episodes/month, P < 0.01), but not in all four patients without the SCN5A mutation (before: 0.43 versus after: 2.94 episodes/month, P = nonsignificant).	Bepridil	70-78	sodium voltage-gated channel alpha subunit 5	Homo sapiens	110-115	
20625312-5	2010	Frequencies of VF episodes were reduced after treatment with low-dose bepridil in all three patients with the SCN5A mutation (before: 0.33 versus after: 0.02 episodes/month, P < 0.01), but not in all four patients without the SCN5A mutation (before: 0.43 versus after: 2.94 episodes/month, P = nonsignificant).	Bepridil	70-78	sodium voltage-gated channel alpha subunit 5	Homo sapiens	229-234	
20625312-7	2010	Treatment with bepridil prevented recurrence of VF along with improvement of ST elevation and LAS40 in patients with Brugada syndrome with the SCN5A mutation.	Bepridil	15-23	sodium voltage-gated channel alpha subunit 5	Homo sapiens	143-148